Know Cancer

or
forgot password

Visualizing VEGF Producing Lesions in Von Hippel-Lindau Disease


N/A
18 Years
N/A
Not Enrolling
Both
Von Hippel-Lindau Disease, Hemangioblastoma, Renal Cell Carcinoma, Pheochromocytoma, Pancreatic Neuroendocrine Tumor

Thank you

Trial Information

Visualizing VEGF Producing Lesions in Von Hippel-Lindau Disease


Inclusion Criteria:



- clinically or genetically proven VHLD

- at least 1 measurable, VHL associated lesion in the CNS

- routine MRI of the CNS ≤ 6 weeks before inclusion

- routine CT or MRI of upper abdomen ≤ 3 months before inclusion or planned ≤ 3 months
after 89Zr-bevacizumab PET scan

- age ≥ 18 years

- written informed consent must be given according to good clinical practice (GCP), and
local regulations

Exclusion Criteria:

- pregnancy

- any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol, those conditions should be discussed
with the patient before registration in the trial

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Detection rate of VHL associated lesions with 89Zr-bevacizumab PET scans in patients with VHLD

Outcome Time Frame:

An 89Zr-bevacizumab PET scan will be performed within 6 weeks after routine MRI CNS investigation, MRI will be repeated within 12 months.

Safety Issue:

No

Principal Investigator

Sjoukje Oosting, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Medical Centre Groningen

Authority:

Netherlands: Medical Ethics Review Committee (METC)

Study ID:

METc2009.119

NCT ID:

NCT00970970

Start Date:

September 2009

Completion Date:

November 2012

Related Keywords:

  • Von Hippel-Lindau Disease
  • Hemangioblastoma
  • Renal Cell Carcinoma
  • Pheochromocytoma
  • Pancreatic Neuroendocrine Tumor
  • Vascular endothelial growth factor
  • von Hippel Lindau disease
  • molecular imaging
  • biomarker
  • Carcinoma
  • Carcinoma, Renal Cell
  • Von Hippel-Lindau Disease
  • Pheochromocytoma
  • Hemangioblastoma
  • Neuroendocrine Tumors
  • Adenoma, Islet Cell

Name

Location